ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on
the Inc. 2024 Best in Business list in the Health Products
category. Inc.’s annual Best in Business Awards celebrate the
exceptional achievements and contributions of companies that have
made an impact on their industries and society at large.
This recognition underscores ChromaDex's industry-leading NAD+
research and its expanding portfolio of healthy aging products
featuring Niagen® (patented nicotinamide riboside or NR), the most
efficient and high-quality NAD+ precursor. Such products include
the direct-to-consumer dietary supplement, Tru Niagen®, and the
newly unveiled pharmaceutical-grade Niagen IV.
“Our mission is to help people around the world to age better,
and this honor reflects the progress we’re making toward achieving
that goal,” said ChromaDex CEO and Founder of Tru Niagen, Rob
Fried.
The Inc. Best in Business list recognizes companies that,
through exceptional execution, have achieved significant milestones
and core business wins. Best in Business can be found online at
inc.com/best-in-business and will be in the upcoming winter print
edition of Inc. magazine.
“For over 40 years Inc. has been committed to recognizing
America’s most dynamic businesses and honoring the great work they
do. These businesses have had a profound impact on their
industries, solving important problems, and shaping the future of
business in ways that will have lasting effects,” says Inc.
editor-in-chief Mike Hofman.
For additional information on ChromaDex and the science behind
Niagen, please visit www.chromadex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to product development.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. Risks that contribute to the uncertain nature of these
forward-looking statements include the impact of the COVID-19
pandemic on our business and the global economy; our history of
operating losses and need to obtain additional financing; the
growth and profitability of our product sales; our ability to
maintain sales, marketing and distribution capabilities; changing
consumer perceptions of our products; our reliance on a single or
limited number of third-party suppliers; and the risks and
uncertainties associated with our business and financial condition.
More detailed information about ChromaDex and the risk factors that
may affect the realization of forward-looking statements is set
forth in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, composed of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor,
safety, quality, and transparency, ChromaDex is the innovator
behind its clinically proven flagship ingredient, Niagen (patented
nicotinamide riboside, or NR), the most efficient and
superior-quality NAD+ booster available.
Niagen® is the active ingredient in ChromaDex’s consumer
products, sold as the brand Tru Niagen®, the number one
healthy-aging NAD+ supplement in the United States†. Clinically
proven to increase NAD+ levels, Tru Niagen is helping people around
the world transform the way they age (available at
www.truniagen.com). ChromaDex supplies pharmaceutical-grade Niagen®
to U.S. FDA-registered 503B outsourcing facilities, which compound
and distribute intravenous and injectable Niagen® for clinics.
These pharmaceutical-grade Niagen® products, known as Niagen IV and
Niagen injections, are available exclusively at clinics with a
prescription (www.niagenplus.com).
ChromaDex’s robust patent portfolio protects NR and other NAD+
precursors. ChromaDex maintains a website at www.chromadex.com,
where copies of press releases, news, and financial information are
regularly published.
†Based on the top-selling dietary supplement brands by revenue
per the largest U.S. e-commerce marketplace (as of
3/1/2023-2/29/2024).
About Inc.
Inc. is the leading media brand and playbook for the
entrepreneurs and business leaders shaping our future. Through its
journalism, Inc. aims to inform, educate, and elevate the profile
of our community: the risk-takers, the innovators, and the
ultra-driven go-getters who are creating our future. Inc.'s
award-winning work achieves a monthly brand footprint of more than
40 million across a variety of channels, including events, digital,
print, video, podcasts, newsletters, and social media. Its
proprietary Inc. 5000 list, produced every year since its launch as
the Inc. 100 in 1982, analyzes company data to rank the
fastest-growing privately held businesses in the United States. The
recognition that comes with inclusion on this and other prestigious
Inc. lists, such as Female Founders and Power Partners, gives the
founders of top businesses the opportunity to engage with an
exclusive community of their peers, and credibility that helps them
drive sales and recruit talent. For more information, visit
www.inc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241203087239/en/
ChromaDex Media Contact: Kendall Knysch, Senior Director
of Media Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Ben Shamsian Lytham
Partners 646-829-9701 shamsian@lythampartners.com
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 11 2024 まで 12 2024
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 12 2023 まで 12 2024
